The Hidden Metabolism Inside Your DNA
Cell Biology · March 2026
For decades, the cell nucleus was understood as a domain with one primary concern: the genome. Its business was DNA — storing it, reading it, copying it, repairing it. Metabolism, by contrast, happened elsewhere. The enzymes that break down sugars, build amino acids, and generate the chemical currency of cellular energy were thought to belong to the cytoplasm, the mitochondria, the spaces between organelles. The nucleus was clean. Separate. A library, not a kitchen.
That division has now been overturned. In a study published by researchers at the Center for Genomic Regulation (CRG) in Barcelona, scientists found hundreds of metabolic enzymes sitting directly on human DNA inside the nucleus — not passing through, not visiting briefly, but bound to chromatin, the protein-DNA complex that makes up chromosomes. Different cell types have different configurations of these enzymes. Different cancers have different configurations. Some enzymes cluster specifically at the sites of DNA damage, arriving in groups when a chromosome breaks.
What the nucleus has been quietly running, it turns out, is a second metabolism — one that nobody had been looking for.
Background: What Metabolic Enzymes Do — and Where They Were Supposed to Do It
Metabolism is the sum of all chemical reactions inside a cell. It covers the breaking down of nutrients to extract energy, the synthesis of building blocks for proteins and nucleic acids, the detoxification of reactive byproducts, and the generation of the small molecules that serve as signals and switches throughout the cell. The enzymes that carry out these reactions are among the most well-studied proteins in biology — many were characterised biochemically in the 1950s and 1960s, long before molecular genetics.
In the classical picture, metabolic enzymes live and work in specific cellular compartments that match their function: glycolytic enzymes (breaking down glucose) in the cytoplasm; TCA cycle enzymes (generating cellular energy) in the mitochondrial matrix; fatty acid synthesis enzymes in the cytoplasm and smooth endoplasmic reticulum. The nucleus, by contrast, was understood to contain DNA, histones, transcription factors, RNA polymerases, and the machinery of gene regulation — but not metabolic enzymes in any systematic, functional sense.
This was not entirely naive. There were scattered prior reports of individual metabolic enzymes found in the nucleus under specific conditions. The enzyme GAPDH (glyceraldehyde-3-phosphate dehydrogenase), a workhorse of glucose metabolism, had been reported in the nucleus in some contexts. Enzymes involved in nucleotide synthesis — the building blocks of DNA and RNA — made obvious sense near the genome. But these were considered exceptions, oddities, possible contamination artefacts, or moonlighting functions of primarily cytoplasmic enzymes. No one had systematically asked: are hundreds of metabolic enzymes a regular feature of the nuclear environment?
The Discovery: A Systematic Census of the Nuclear Proteome
The CRG team approached the question with a technique called chromatin immunoprecipitation followed by mass spectrometry (ChIP-MS) — a method that allows researchers to pull down the entire complement of proteins physically associated with DNA in living cells, then identify every protein present using mass spectrometry's ability to recognise proteins by their unique peptide fragments.
Earlier applications of this kind of approach had focused on specific proteins of interest — a particular transcription factor, a histone modification, a DNA repair protein. The CRG study applied it more broadly: a systematic, unbiased survey of everything bound to chromatin across multiple human cell types, including normal tissue-derived cells and cancer cell lines. The result was not a list of the usual suspects. It was a catalogue that contained, unexpectedly, the bulk of the known metabolic enzyme repertoire — hundreds of enzymes from every major metabolic pathway.
The enzymes were not found in random positions across the chromatin. They were found in non-random, organised patterns. Some were enriched near actively transcribed genes. Some were found at heterochromatin — the densely packed, transcriptionally silent regions of chromosomes. Some co-localised with specific histone modifications. And when the team compared the chromatin-bound metabolic enzyme profiles across different cell types, they found that each had a distinct signature — a set of enzymes that defined its nuclear metabolic state as uniquely as a fingerprint.
The Three Major Findings
1. Metabolic enzymes are a normal, abundant feature of chromatin
The first and most fundamental finding was simply the scale. This was not a handful of enzymes with moonlighting nuclear functions. The researchers identified approximately 800 metabolic enzymes — drawn from virtually every major metabolic pathway — consistently associated with chromatin. Enzymes from glycolysis. From the TCA cycle. From nucleotide metabolism. From lipid synthesis. From amino acid biosynthesis. From one-carbon metabolism. The nucleus, rather than being free of metabolism, appeared to be saturated with it.
Crucially, the team used multiple orthogonal methods to confirm that the associations were real and not contamination artefacts. Proximity ligation assays confirmed direct spatial adjacency between the enzymes and DNA. Immunofluorescence microscopy showed the enzymes inside nuclei, not outside them. Chromatin fractionation experiments showed the enzymes partitioning with the chromatin-enriched fraction. The associations were not experimental noise — they were a genuine feature of nuclear organisation that had been systematically overlooked.
2. Each tissue and cancer type has a unique nuclear metabolic fingerprint
When the team compared chromatin-associated enzyme profiles across different human cell types — derived from breast, lung, liver, colon, and other tissues, as well as from cancer cell lines derived from each — they found that the profiles were highly tissue-specific. A breast cell and a lung cell do not just have different gene expression profiles (which was already known). They have different nuclear metabolic profiles — different sets of metabolic enzymes bound to their chromatin, in different abundances and at different chromosomal locations.
More striking still: cancer cells showed dramatically altered nuclear metabolic fingerprints compared to their normal tissue counterparts. This was not simply a reflection of the fact that cancer cells have altered metabolism generally (the Warburg effect — cancer cells favouring glycolysis even in the presence of oxygen — is one of the most studied phenomena in cancer biology). The differences were specifically in the nuclear compartment, independently of whole-cell metabolic profiles. Some enzymes enriched on chromatin in normal breast tissue were absent or depleted in breast cancer cells. Others were cancer-specific — present on chromatin only in the tumour, not in the normal tissue.
This means that cancers can be distinguished not only by their genetic mutations, their protein expression profiles, or their metabolic rates — but by their nuclear metabolic fingerprints. Whether these fingerprints are diagnostically useful remains to be established, but the finding raises the possibility that a cancer's nuclear metabolic state may influence its behaviour, its aggressiveness, and potentially its response to treatment.
3. Metabolic enzymes cluster at DNA damage sites
The third finding may ultimately be the most consequential for understanding how metabolism and the genome interact. When the researchers induced DNA double-strand breaks in cells — the most severe form of DNA damage — and then profiled chromatin-associated proteins at the break sites, they found that more than 50 metabolic enzymes were specifically recruited to the damage, arriving in clusters around the break within minutes.
This is not what enzymes responsible for energy metabolism are supposed to do. Their presence at DNA breaks — reliably, reproducibly, in clusters — implies that they are performing a function there. The most parsimonious explanation, supported by the metabolite-histone connection above, is that some of these enzymes are locally generating metabolites needed for DNA repair or for the chromatin remodelling that makes DNA repair possible. Histone modifications at break sites are essential for DNA damage signalling and for the recruitment of repair factors. If the enzyme that produces the substrate for a key histone modification is sitting right there — next to the break — it can respond faster, with higher local concentration, than if it had to rely on diffusion of metabolites from the cytoplasm.
The Metabolite-Chromatin Connection: Why This Makes Biological Sense
The discovery is surprising, but it is not arbitrary. Once the existence of nuclear metabolic enzymes is established, a mechanistic framework for why they are there becomes available — and it draws on some of the most active areas of current cell biology.
Chromatin is not a static structure. It is continuously being opened and closed, decorated and stripped of chemical modifications, in response to signals about cellular state, developmental stage, and environmental conditions. The marks that control chromatin accessibility — histone acetylation, methylation, phosphorylation, ubiquitylation — are all applied and removed by enzymes that require metabolite substrates and cofactors. Acetyl-CoA is required for histone acetylation (which opens chromatin). SAM is required for histone methylation (which can open or close chromatin, depending on which histone residue is methylated). NAD⁺ is required for histone deacetylation by sirtuins. α-ketoglutarate and 2-hydroxyglutarate are substrates and inhibitors of histone demethylases.
All of these are metabolites — products of the reactions that metabolic enzymes catalyse. The key insight the new study provides is that the enzymes producing these metabolites are not randomly distributed in the cytoplasm, forcing metabolites to diffuse long distances to reach their chromatin targets. They are sitting directly on the chromatin, where their products can be immediately used. This is a form of metabolic channelling — the biological strategy of colocalising sequential enzymes and their substrates to achieve efficiency and specificity — applied directly to genome regulation.
Key Enzymes of Interest: From Metabolic Pathway to Chromosome
Implications for Cancer
The discovery lands in a field that is already grappling with the metabolic abnormalities of cancer. Oncologists have known for decades that cancer cells alter their metabolism — but the prevailing interpretation was largely that these alterations were consequences of rapid proliferation rather than drivers of it. The IDH mutation story was the first clear demonstration that a metabolic enzyme mutation could be the primary oncogenic event, rewriting the epigenome through an aberrant metabolite. The new nuclear metabolic fingerprint data extends this logic to the entire metabolic proteome on chromatin.
The practical implications are several. First, the fingerprint itself may be diagnostically informative. If cancers of different origins — and potentially different grades or stages — show distinct nuclear metabolic profiles, then those profiles could supplement or refine existing diagnostic criteria. Second, if specific chromatin-bound metabolic enzymes are driving the gene expression changes that define a tumour's behaviour, they become potential therapeutic targets — not because of their metabolic function but because of their epigenetic function. Third, the clustering of metabolic enzymes at DNA damage sites implies that cancer cells may be modifying their DNA repair capacity metabolically — a finding with implications for how tumours resist genotoxic chemotherapy and radiation.
The Broader Question: Is the Nucleus Metabolically Autonomous?
Beyond the immediate cancer implications, the discovery raises a fundamental question about cellular organisation. The classical model holds that the nucleus is metabolically dependent on the cytoplasm — it imports ATP, receives metabolites by diffusion, and relies on cytoplasmic enzymes for metabolite production. But if hundreds of metabolic enzymes are resident on chromatin, performing reactions locally, then the nucleus may have a degree of metabolic autonomy — the ability to regulate its own metabolite concentrations independently of the cytoplasmic metabolic state.
This would have profound consequences for our understanding of gene regulation. It would mean that the acetyl-CoA concentration experienced by histone acetyltransferases in the nucleus is not simply a readout of total cellular acetyl-CoA but of a local, nuclear-specific pool controlled by the local metabolic enzymes on chromatin. Gene regulation, in this view, is not just about transcription factor availability — it is also about the metabolic microenvironment of specific chromosomal regions, shaped by the enzymes that are parked there.
It is a model that is simultaneously more complex and more elegant than what preceded it. The genome and the metabolome are not two separate systems communicating at a distance. They are interleaved — written on top of each other, literally sharing the same physical space.
The Research Team and Methodology
The CRG is one of Europe's leading molecular biology research institutes, with particular expertise in genomics, chromatin biology, and gene regulation. The study combined mass spectrometry proteomics, chromatin biochemistry, and computational analysis of multiple cell type datasets to characterise the nuclear metabolic proteome systematically — an approach requiring both wet-lab protein chemistry and large-scale bioinformatics.
The work builds on a decade of research connecting nuclear metabolism and gene regulation, including prior studies of individual metabolic enzymes in nuclear contexts. The CRG study was the first to apply unbiased proteomics across multiple tissue and cancer types to establish that chromatin-bound metabolic enzymes are a general, systematic feature of nuclear organisation rather than exceptional cases.
What Comes Next
The descriptive catalogue must now be followed by functional experiments: do specific nuclear metabolic enzymes actually affect gene expression when removed from chromatin? Are the metabolite levels near specific genes influenced by the local enzyme population? CRISPR screens removing individual chromatin-associated metabolic enzymes from the nuclear localisation — without affecting their cytoplasmic function — are the next experimental step.
The finding that 50+ metabolic enzymes cluster at DNA double-strand breaks is among the most actionable parts of the study. Which of these enzymes are functionally required for efficient repair? Do cells with depleted nuclear metabolic enzyme pools have impaired DNA repair capacity? If so, this could explain why metabolically perturbed cancer cells are sometimes more or less sensitive to DNA-damaging chemotherapy.
The tissue-specific and cancer-specific nuclear metabolic fingerprints need validation in larger, clinically annotated sample sets. The key question: do nuclear metabolic fingerprint differences correlate with clinical behaviour — tumour grade, metastatic potential, treatment response? If they do, fingerprint profiling could become a molecular pathology tool.
If specific metabolic enzymes are driving oncogenic chromatin states through their nuclear localisation, drugs that disrupt nuclear localisation specifically — without blocking the enzyme's metabolic function — could be a new therapeutic class. The MAT2A-MTAP synthetic lethal story is the nearest clinical precedent; the nuclear metabolic fingerprint data will be searched for similar vulnerability patterns across cancer types.
Is the nuclear metabolic proteome conserved across species? Does it change during development — as embryonic cells specialise into different tissue types, do their nuclear metabolic fingerprints change in ways that parallel or drive their gene expression changes? These are foundational developmental biology questions now opened by the discovery.
Why This Matters: A Shift in the Map
Science proceeds in two modes. Most of the time, it fills in details — it confirms or quantifies things that were already broadly expected, adding resolution to a picture whose outline was already clear. Occasionally, it changes the outline. The hidden nuclear metabolism discovery is, if confirmed and extended, one of the latter.
The textbook picture of a cell has a clean division: the nucleus manages information; the cytoplasm manages chemistry. That division was always somewhat artificial — nuclear processes consume ATP, use metabolite co-factors, depend on the cell's metabolic state. But the sheer scale and specificity of the new findings — hundreds of enzymes, tissue-specific patterns, cancer-specific alterations, damage-site clustering — suggests the integration is far deeper than the textbook implied. The nucleus is not a computer sitting above a chemical plant. It is both.
For cancer medicine, the implication is that the epigenetic reprogramming that defines tumour behaviour — the silencing of tumour suppressors, the activation of oncogenes, the chromatin remodelling that allows cancer cells to resist treatment and evade the immune system — is not purely an epigenetic story. It is also a metabolic story, playing out on the DNA itself. The drugs that will ultimately control it may come as much from metabolic chemists as from epigenetic biologists.
The genome and the metabolome have been understood, and studied, and medicated as if they were two different countries. The new data suggests they share a border — and that the border runs straight through the chromosome.
Comments
Post a Comment